Generation Bio aims to do what no other gene therapy platform has yet accomplished: to deliver scalable, re-dosable, non-viral gene therapy for patients living with rare and prevalent diseases. Generation Bio went public in June 2020 (NASDAQ: GBIO).
| Headquarters | Cambridge, MA |
| Website | www.generationbio.com |
| Pipeline | Preclinical |
| @generationbio |